Results 201 to 210 of about 24,787 (310)

Clinical Trial Comparison of Dupilumab and Nemolizumab for Prurigo Nodularis FDA-Approved Biologic Therapy Selection in Prurigo Nodularis. [PDF]

Clin Drug Investig
Robertson A, Rohan C.
europepmc   +1 more source

Use of Dupilumab to Manage Antibody-Drug Conjugate–Induced Cutaneous Toxicities

Ian Nykaza, Stephen W. Dusza, Jonathan E. Rosenberg, Gopa Iyer, Emily Feld, Sarat Chandarlapaty, Komal Jhaveri, Kristine Peregrino Lacuna, Devika Gajria, Megan Bielawa, Alina Markova, Allison Gordon   +11 more
openalex   +2 more sources

Effective Management of Recalcitrant Hailey–Hailey Disease With Risankizumab

International Journal of Dermatology, EarlyView.
Joy Justice, Adriana Della Porta, Eva Niklinska, Jami L. Miller   +3 more
wiley   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study. [PDF]

Laryngoscope Investig Otolaryngol
Zheng W, Arslan M, Zhu C, Guirguis C, Spielman DB.   +4 more
europepmc   +1 more source

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham, Jonathan I. Silverberg, Marjolein De Bruin‐Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E. Myers, Pinaki Biswas, Saleem A. Farooqui, Melissa Watkins, Herwig Koppensteiner   +14 more
wiley   +1 more source

Case Report Concerning a Varicella Zoster Virus Infection in a Six-year-old Child Receiving Dupilumab for Atopic Dermatitis. [PDF]

Acta Derm Venereol
Rangen JK, Dalager MG.
europepmc   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang, Nicolaas P. A. Zuithoff, Inge M. Haeck, Veroniek E. M. Harbers, Simone Stadhouders‐Keet, Klaziena Politiek, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Hoo‐Yin Lam, Anne‐Moon van Tuyll van Serooskerken, Shiarra M. Stewart, Antoni Gostynski, Annebeth Flinterman, Berit Velstra, Wouter R. H. Touwslager, Francine C. van Erp, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller, Marlies de Graaf   +18 more
wiley   +1 more source

Dupilumab therapy facilitates the histopathologic diagnosis of dermatomyositis in a patient with intercurrent severe atopic dermatitis and dermatomyositis. [PDF]

JAAD Case Rep
Wilson C, Castillo S, Ndoricimpa Y, Malone JC, Strickley J.   +4 more
europepmc   +1 more source

Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab [PDF]

Carlota Gonzalez-Lluch, María Basagaña, Laura Pardo, Paula Toro, Agnes Hernández-Biette, Carlos Martínez‐Rivera, Ignasi García-Olivé   +6 more
openalex   +1 more source